Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiSARRO-R: APR-246 + PLD in Platinum-Resistant Ovarian Cancer
NCT03268382Phase 2Completed
- Sponsor
- Aprea Therapeutics
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of eprenetapopt in High-Grade Serous Ovarian Carcinoma (HGSOC), sponsored by Aprea Therapeutics. Started Jul 2017; status: completed.
02
Drugs
eprenetapopt
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT03268382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268382.